Barclays Initiates Coverage On Qiagen with Overweight Rating, Announces Price Target of $55

-3.33%

QIAGEN NV

QGEN

0.00

Barclays analyst Luke Sergott initiates coverage on Qiagen (NYSE: QGEN) with a Overweight rating and announces Price Target of $55.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Qiagen (NYSE:QGEN) Valuation in Focus as Forensic Automation and Lab Milestones Drive Future Growth Prospects

QIAGEN Signs Agreement To Acquire Parse Biosciences For Upfront Payment Of ~$225M In Cash; Parse Shareholders Entitled For Additional Milestone Payments Of Up To $55M

Qiagen Raises FY2025 Adj EPS Guidance from $2.35 to $2.38 vs $2.37 Est

QIAGEN Announces Plans To Complete A $500M Synthetic Share Repurchase In Early January 2026

QIAGEN CEO Thierry Bernard To Step Down After Successor Is Named

Qiagen N.V. Shares Resume Trade

CORRECTION: QIAGEN Acquires Parse Biosciences For ~$225M

Qiagen Sees Q4 Adj EPS $0.60 vs $0.61 Est